SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced on Oct. 5, 2026, that it has submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market.
This development is significant for the surgical robotics industry, which has long been dominated by high-cost systems that limit access to advanced minimally invasive surgery. SS Innovations aims to make robotic surgery affordable and accessible to a larger segment of the global population. The SSi Mantra system is a modular, multi-arm robotic platform with advanced features such as 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient information display. It also includes a virtual real-time image of the robotic patient side arm carts and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console offers portability and telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries, and a vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures, demonstrating its versatility and potential to support a wide range of specialties, including cardiac surgery.
For investors and the medical community, the FDA submission marks a critical step toward U.S. commercialization. If cleared, the SSi Mantra could provide a cost-effective alternative to existing robotic surgical systems, potentially increasing competition and driving down costs. This could lead to broader adoption of robotic surgery in hospitals of varying sizes and in underserved markets. The company’s focus on affordability and accessibility aligns with global trends toward value-based care and expanding access to advanced medical technologies. Success in the U.S. market could also accelerate SS Innovations’ global expansion, given its headquarters in India and its U.S. corporate status. The company’s product range includes the SSi Mantra and the SSi Mudra surgical instruments, which support a variety of procedures. For more information, visit the company’s website at ssinnovations.com or its LinkedIn page. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. To view the full press release, visit https://ibn.fm/A6dJ8.
The announcement was distributed through TechMediaWire, a specialized communications platform focused on pioneering public and private companies driving the future of technology. TechMediaWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. As the FDA review progresses, stakeholders will be watching closely for a decision in early 2027, which could reshape the competitive landscape of surgical robotics and expand patient access to advanced surgical care.
